Bulløse hudsygdomme
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Bulløse hudsygdomme. / Kaae, Jeanette; Bech, Rikke; Taudorf, Elisabeth Hjardem; Beck, Shiva; Vestergaard, Christian; Ring, Hans Christian; Jemec, Gregor B.
I: Ugeskrift for Laeger, Bind 184, Nr. 41, V06220400, 2022.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Bulløse hudsygdomme
AU - Kaae, Jeanette
AU - Bech, Rikke
AU - Taudorf, Elisabeth Hjardem
AU - Beck, Shiva
AU - Vestergaard, Christian
AU - Ring, Hans Christian
AU - Jemec, Gregor B
PY - 2022
Y1 - 2022
N2 - This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.
AB - This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.
KW - Autoimmune Diseases
KW - Azathioprine/adverse effects
KW - Glucocorticoids
KW - Humans
KW - Methotrexate/adverse effects
KW - Pemphigus/chemically induced
KW - Rituximab/therapeutic use
KW - Skin Diseases, Vesiculobullous/chemically induced
M3 - Review
C2 - 36254827
VL - 184
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 41
M1 - V06220400
ER -
ID: 326028285